VRDN — Viridian Therapeutics, Inc.\DE
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1590750 ·
Last close
$19.74
Market Cap
$2.18B
52W High
$20.88
52W Low
$13.18
ADV30
2,198,846
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 141,000 | — | -116,169,000 | -104,901,000 | 789,017,000 | 176,346,000 | 153,009,000 |
| Dec 2025 | 132,000 | — | -122,749,000 | -120,355,000 | 899,418,000 | 212,382,000 | 177,251,000 |
| Sep 2025 | 70,570,000 | — | -40,013,000 | -34,599,000 | 577,138,000 | 169,647,000 | 74,168,000 |
| Jun 2025 | 75,000 | — | -106,767,000 | -100,735,000 | 582,324,000 | 117,324,000 | 67,155,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-276,391,000
Investing CF
$-37,563,000
Financing CF
$426,742,000
CapEx
$-495,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.29
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,338,458,000
Inventory
—
Receivables
$70,000,000
ST Investments
$662,270,000
EBIT TTM
$-337,659,000
Pretax Income TTM
$-342,601,000
Interest Exp TTM
$4,942,000
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$70,918,000
EBITDA
$-385,233,984
Free Cash Flow
$-182,550,752
Enterprise Value
$1,505,334,784
Total Cash
$762,180,992
Total Debt
$53,350,000
Shares Out
110,427,682
Trailing EPS
$-3.35
Book Value
$4.92
ROE
-58.1%
ROA
-33.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 70,849,000 | -363,395,000 | -342,601,000 | 899,418,000 | 177,251,000 | — | -276,391,000 |
| Dec 2024 | 302,000 | -299,035,000 | -269,949,000 | 742,403,000 | 70,764,000 | — | -232,319,000 |
| Dec 2023 | 314,000 | -254,450,000 | -237,734,000 | 490,424,000 | 48,402,000 | — | -184,170,000 |
| Dec 2022 | 1,772,000 | -134,304,000 | -129,874,000 | 435,091,000 | 40,027,000 | — | -93,838,000 |
TTM Snapshot
Revenues TTM
$1,561,000
NetIncome TTM
$-167,297,000
OpCashFlow TTM
$0
Assets (Latest)
$742,403,000
Forward EPS
$-2.63
Max Pain — expiry 2026-07-17
max pain strike: $17.00 · spot: $19.74 · call oi: 10,662 · put oi: 1,539
Expected Move to 2026-07-17:
±$1.55
(7.85%) —
implied range
$18.19 –
$21.29
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings, Inc. | $2.13B | $36.84 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $2.23B | $10.20 | — |
| SNDX | Syndax Pharmaceuticals Inc | $2.09B | $23.61 | — |
| GIFOF | Grifols SA | $2.29B | $8.85 | — |
| ABCL | AbCellera Biologics Inc. | $2.08B | $6.80 | — |
News headlines (Yahoo Finance, 1h cache)
Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone
2026-07-06 17:21 · Yahoo
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
2026-07-01 14:41 · Yahoo
Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says
2026-06-30 15:53 · Yahoo
Viridian may have edge over Amgen in eye drug showdown, analysts argue
2026-06-30 11:33 · Yahoo
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Hopes for Renewed US-Iran Diplomacy
2026-06-29 12:56 · Yahoo
Comcast, Viridian Therapeutics jump premarket; Doximity slips
2026-06-29 12:09 · Yahoo
DRI Healthcare Comments on Viridian's FDA Approval and Launch of Lumvoa™ (veligrotug-vvze)
2026-06-29 11:00 · Yahoo
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval
2026-06-26 22:57 · Yahoo
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
2026-06-26 22:00 · Yahoo
Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M
2026-05-21 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.